Wearing of face shields proves golden as a preventive measure, reducing not only the number of SARS-CoV-2 infections but also that of hospital-acquired infections among healthcare personnel, as shown in a study reported at the 2020 virtual IDWeek meeting.
Tocilizumab (TCZ) therapy appears to be effective in patients at risk of cytokine release syndrome (CRS) from the novel coronavirus disease (COVID-19), suggests a study presented at ID Week 2020. Those receiving TCZ in a nonintensive care unit (non-ICU) setting show better response than ICU patients.
Bezlotoxumab proves to be effective at thwarting the return of Clostridium difficile infection in high-risk populations, namely individuals with one or more risk factors for recurrence and patients who are immunocompromised, within 90 days and up to 24 weeks after initial infusion, respectively, according to two studies reported at the 2020 virtual IDWeek meeting.
An under-the-radar consequence that the novel coronavirus pandemic (COVID-19) may bring is the spike in inappropriate antibiotic prescriptions, particularly in urgent care and emergency departments, according to a new study presented at the recently concluded 2020 IDWeek Virtual Conference (ID Week 2020).
People living with HIV (PLHIV) are often uncomfortable talking to their healthcare providers (HCPs) about issues related to their condition, reports a new study presented at the recently concluded 2020 IDWeek Virtual Conference (ID Week 2020). In turn, PLHIVs tend to suffer from worse quality of life (QOL).